We are live on ! Find out more
VBIO

Valion Bio
VBIO

6 hedge funds and large institutions have $216K invested in Valion Bio in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more funds holding

Funds holding: 1 → 6 (+5)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

397% more capital invested

Capital invested by funds: $43.4K → $216K (+$172K)

14.05% more ownership

Funds ownership: 0.7% → 14.75% (+14%)

Holders
6
Holders Change
+5
Holders Change %
+500%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SSWM
Sheets Smith Wealth Management
North Carolina
+$246K
2
WAM
Warberg Asset Management
Illinois
+$228K
3
UBS Group
UBS Group
Switzerland
+$52.6K
4
BFM
Boothbay Fund Management
New York
+$17.5K
5
E
Ergoteles
New York
+$17.5K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$17K
2
TSS
Two Sigma Securities
New York
-$8.05K
3
Bank of America
Bank of America
North Carolina
-$8

VBIO Hedge Fund Activity: Q1 2023 in Review

6 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q1 2023, worth a combined $216K — up 397% from $43.4K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VBIO positions and 1 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sheets Smith Wealth Management, opening a new position worth an estimated $246K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $17K sold.

  • 6 institutional investors held Valion Bio (VBIO) as of Q1 2023, up from 1 in Q4 2022.
  • Funds reported $216K of Valion Bio stock for Q1 2023, up 397% quarter-over-quarter.
  • 6 funds opened new Valion Bio positions in Q1 2023 and 1 closed out, a net change of +5 holders.
  • The largest Valion Bio buyer in Q1 2023 was Sheets Smith Wealth Management, an estimated $246K added.
  • The largest Valion Bio seller in Q1 2023 was Renaissance Technologies, an estimated $17K sold.

Based on aggregated 13F filings for Q1 2023.